A share price of KalVista Pharmaceuticals Inc [KALV] is currently trading at $12.34, up 23.40%. An important factor to consider is whether the stock is rising or falling in short-term value. The KALV shares have gain 17.64% over the last week, with a monthly amount drifted -4.27%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
KalVista Pharmaceuticals Inc [NASDAQ: KALV] stock has seen the most recent analyst activity on June 15, 2020, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $30. Previously, SVB Leerink started tracking the stock with Outperform rating on July 29, 2019, and set its price target to $31. On March 20, 2019, Needham initiated with a Buy rating and assigned a price target of $35 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $30 on October 30, 2018. Cantor Fitzgerald initiated its recommendation with a Overweight. BTIG Research started tracking with a Buy rating for this stock on August 31, 2017, and assigned it a price target of $18.
KalVista Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $7.21 and $16.88. Currently, Wall Street analysts expect the stock to reach $26 within the next 12 months. KalVista Pharmaceuticals Inc [NASDAQ: KALV] shares were valued at $12.34 at the most recent close of the market. An investor can expect a potential return of 110.7% based on the average KALV price forecast.
Analyzing the KALV fundamentals
Gross Profit Margin for this corporation currently stands at 0.3% with Operating Profit Margin at -128.99%, Pretax Profit Margin comes in at -117.55%, and Net Profit Margin reading is -117.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.71, Equity is -0.97 and Total Capital is -0.88. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.95 points at the first support level, and at 9.55 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.05, and for the 2nd resistance point, it is at 13.75.
Ratios To Look Out For
To put it in perspective, the Current Ratio for KalVista Pharmaceuticals Inc [NASDAQ:KALV] is 8.55. On the other hand, the Quick Ratio is 8.55, and the Cash Ratio is 1.42.
Transactions by insiders
Recent insider trading involved Palleiko Benjamin L, CHIEF EXECUTIVE OFFICER, that happened on Sep 09 ’24 when 7352.0 shares were sold. CHIEF MEDICAL OFFICER, Audhya Paul K. completed a deal on Aug 23 ’24 to sell 2135.0 shares. Meanwhile, CHIEF DEVELOPMENT OFFICER Yea Christopher sold 1916.0 shares on Aug 23 ’24.